Concepedia

Author

Ouzama Henry

GlaxoSmithKline (United States)

Also Known As

Henry, Ouzama, Ouzama Henry, Ouzama N Henry

33

Publications

466

Citations

12

H-Index

6

Concepts

All Affiliations

GlaxoSmithKline (United States)GlaxoSmithKline (Belgium)Charles UniversityGlaxoSmithKline (Germany)Mount Carmel Health
OH

About

Ouzama Henry is an author at GlaxoSmithKline (United States) specializing in vaccine development, epidemiology, and vaccine safety.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

42

2

Epidemiology

1

1

42

3

Vaccine Development

1

1

42

4

Infection Control

1

1

42

5

Vaccination

1

1

42

Ouzama Henry

×

15

Publications

424

Citations

12

H-Index

YearCitations

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial

Zourab Bebia, Osvaldo Reyes, Robert Jeanfreau,

The Journal of Infectious Diseases

2023

60

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial

Geeta K. Swamy, Torri D. Metz, Kathryn M. Edwards,

Vaccine

2020

59

Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women

Tino F. Schwarz, Casey Johnson, Christine Grigat,

The Journal of Infectious Diseases

2021

43

Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial

Michael Povey, Ouzama Henry, Marianne A. Riise Bergsaker,

The Lancet Infectious Diseases

2019

42

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

Remon Abu‐Elyazeed, William Jennings, Randall Severance,

Human Vaccines & Immunotherapeutics

2018

37

Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4–6 Years After a First Dose: Results From a Phase 2 Trial

Geert Leroux‐Roels, Zourab Bebia, Cathy Maes,

Clinical Infectious Diseases

2019

32

Association of Group B <i>Streptococcus</i> (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort, Matched Case-Control Study

Shabir A. Madhi, Alane Izu, Gaurav Kwatra,

Clinical Infectious Diseases

2020

27

One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life

Ouzama Henry, Jerzy Brzostek, Hanna Czajka,

Vaccine

2017

26

Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial

Sanjay Lalwani, Sukanta Chatterjee, Sundaram Balasubramanian,

BMJ Open

2015

19

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

Nicola P. Klein, Remon Abu‐Elyazeed, Michael Povey,

Journal of the Pediatric Infectious Diseases Society

2019

17

Page 1